LIPOCINE INC (LPCN) Stock Price, Forecast & Analysis
USA - NASDAQ:LPCN - US53630X2036 - Common Stock
LPCN Key Statistics, Chart & Performance
The current stock price of LPCN is 2.87 USD. In the past month the price decreased by -4.97%. In the past year, price decreased by -41.31%.
LPCN Latest News, Press Relases and Analysis
LPCN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.62 | 970.39B | ||
| JNJ | JOHNSON & JOHNSON | 18.88 | 471.87B | ||
| MRK | MERCK & CO. INC. | 10.55 | 232.09B | ||
| PFE | PFIZER INC | 7.83 | 142.48B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.95B | ||
| ZTS | ZOETIS INC | 19.06 | 53.55B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.84B | ||
| VTRS | VIATRIS INC | 4.6 | 12.50B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.97 | 10.48B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.84 | 7.96B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.07B |
Related stock screener links
About LPCN
Company Profile
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 16 full-time employees. The company went IPO on 2014-03-21. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. The company is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Company Info
LIPOCINE INC
675 S Arapeen Dr Ste 202
Salt Lake City UTAH 84108 US
CEO: Mahesh V. Patel
Employees: 16
Phone: 18019947383
LIPOCINE INC / LPCN FAQ
What does LIPOCINE INC do?
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 16 full-time employees. The company went IPO on 2014-03-21. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. The company is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Can you provide the latest stock price for LIPOCINE INC?
The current stock price of LPCN is 2.87 USD. The price increased by 1.77% in the last trading session.
Does LPCN stock pay dividends?
LPCN does not pay a dividend.
What is the ChartMill rating of LIPOCINE INC stock?
LPCN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists LPCN stock?
LPCN stock is listed on the Nasdaq exchange.
What is LIPOCINE INC worth?
LIPOCINE INC (LPCN) has a market capitalization of 15.56M USD. This makes LPCN a Nano Cap stock.
LPCN Technical Analysis
LPCN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to LPCN. While LPCN has a great health rating, there are worries on its profitability.
LPCN Financial Highlights
Over the last trailing twelve months LPCN reported a non-GAAP Earnings per Share(EPS) of 0.51. The EPS increased by 168.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.27% | ||
| ROE | -26.32% | ||
| Debt/Equity | 0 |
LPCN Forecast & Estimates
8 analysts have analysed LPCN and the average price target is 7.52 USD. This implies a price increase of 162.11% is expected in the next year compared to the current price of 2.87.
For the next year, analysts expect an EPS growth of -222.86% and a revenue growth -88.42% for LPCN